Evidence map›Paper›PMID 31562490›Full record

ArticleNature immunology2019

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, Mohamed R Daha, Brian V Geisbrecht, Berhane Ghebrehiwet, Piet Gros, George Hajishengallis, V Michael Holers, Markus Huber-Lang and 12 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Dimitrios C MastellosNational Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.ORCID http://orcid.org/0000-0002-6634-3271
Anna M BlomDepartment of Translational Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-1348-1734
E Sander ConnollyDepartment of Neurological Surgery, Columbia University, New York, NY, USA.
Mohamed R DahaLeiden University Medical Center, Leiden, Netherlands.
Brian V GeisbrechtDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Berhane GhebrehiwetDepartment of Medicine, Division of Rheumatology, Allergy and Immunology, Stony Brook University, New York, NY, USA.
Piet GrosDepartment of Chemistry, Faculty of Science, Utrecht University, Utrecht, Netherlands.
George HajishengallisDepartment of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7392-8852
V Michael HolersDivision of Rheumatology, Departments of Medicine and Immunology, University of Colorado School of Medicine, Denver, CO, USA.
Markus Huber-LangInstitute of Clinical and Experimental Trauma immunology, University of Ulm, Ulm, Germany.
Taroh KinoshitaResearch Institute for Microbial Diseases Osaka University and Laboratory of Immunoglycobiology, Immunology Frontier Research Center, Osaka University, Osaka, Japan.ORCID http://orcid.org/0000-0001-7166-7257
Tom E MollnesDepartment of Immunology, Oslo University Hospital, and University of Oslo, Oslo, Norway.
Robert A MontgomeryDepartment of Surgery, NYU Langone Transplant Institute, New York, NY, USA.
B Paul MorganSystems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, UK.
Bo NilssonDivision of Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden.
Ruben PioProgram in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, IDISNA, CIBERONC, Pamplona, Spain.
Daniel RicklinDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6140-0233
Antonio M RisitanoDepartment of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
Ronald P TaylorDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0003-1578-8382
Alberto MantovaniIstituto Clinico Humanitas, Humanitas University, Milan, Italy.ORCID http://orcid.org/0000-0001-5578-236X
John P A IoannidisMeta-Research Innovation Center at Stanford, and Departments of Medicine, of Health Research and Policy, of Biomedical Data Science, and of Statistics, Stanford University, Stanford, CA, USA.
John D LambrisDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. lambris@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-9370-5776

Funding

Role of complement in kidney disorders: from hemodialysis to transportationP01AI068730 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAMBRIS, JOHN D · 2007 to 2018
$16.0M
NIAID NIH HHS P01 AI068730
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31562490
PMCPMC7368001

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.